Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. reports developments in thermoacoustic biomarker imaging, including its TAEUS® Liver device for measuring liver fat in steatotic liver disease, MASLD and MASH. Company news commonly covers clinical feasibility work comparing TAEUS measurements with MRI-PDFF, device repeatability and reproducibility, and business updates tied to operating results.
NDRA updates also include capital and treasury actions, such as private placement financing and a digital asset treasury strategy involving HYPE token holdings and staking. Corporate news has included strategic-review announcements and Nasdaq listing-compliance matters.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has announced a public offering of 7,143,000 shares of common stock priced at $0.70 per share, aiming to raise approximately $5.0 million before expenses. The underwriter has a 45-day option to purchase an additional 714,286 shares to cover over-allotments, potentially increasing gross proceeds to $5.5 million. The offering is slated to close on December 18, 2020. Funds will be allocated for working capital and general corporate purposes.
ENDRA Life Sciences (NASDAQ:NDRA) announced a proposed underwritten public offering of common stock. The company plans to grant the underwriter a 45-day option to purchase additional shares. The offering is subject to market conditions, with no guarantee on its completion or terms. ENDRA intends to utilize the net proceeds for working capital and general corporate purposes. ThinkEquity is acting as the sole underwriter. A shelf registration statement has been filed with the SEC, and preliminary prospectus materials will also be available.
ENDRA Life Sciences (NASDAQ:NDRA) has received its seventh Chinese patent for TAEUS technology, aimed at addressing clinical needs like Non-Alcoholic Fatty Liver Disease. The new patent, ZL 2016 8 00267062, enhances ENDRA’s intellectual property protection in China, where approximately 30% of the population is affected by liver disease. The company’s patent portfolio now includes 78 assets, with further developments expected in the US and Europe. This patent supports ENDRA’s goal of optimizing hybrid ultrasound and thermoacoustic imaging for various clinical applications.
ENDRA Life Sciences (NASDAQ: NDRA) has signed an exclusive distribution agreement with Quang Phat Technology Science Equipment Co. Ltd. to sell at least 40 TAEUS liver imaging systems in Vietnam. The agreement, effective over three years, hinges on securing FDA clearance and local approvals before sales commence. This marks ENDRA's first commercial agreement in Southeast Asia, aimed at addressing the rising incidence of NAFLD in Vietnam's 96 million population. ENDRA aims to capitalize on its innovative technology to provide non-invasive liver disease diagnostics.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has partnered with Centre Hospitalier Universitaire d'Angers, France, to conduct a clinical study on its Thermo Acoustic Enhanced Ultrasound (TAEUS) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). This study aims to compare TAEUS with standard MRI measures, targeting 75 patients to enhance clinical evidence and support TAEUS commercialization in Europe. NAFLD, affecting over 1 billion globally, poses significant healthcare challenges.
ENDRA Life Sciences (NASDAQ:NDRA) announced that Rocky Vista University College of Osteopathic Medicine has initiated patient scans using its TAEUS system to evaluate Non-Alcoholic Fatty Liver Disease (NAFLD) in Utah. This marks the first real-world use of TAEUS in the U.S. The study aims to analyze 200 volunteers while collecting clinical data to bolster commercialization efforts. ENDRA has received the CE mark for European sales and is seeking FDA clearance in the U.S. The initiative highlights TAEUS's potential in addressing a significant clinical need for non-invasive liver assessments.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will present at the virtual Fall Investor Summit from November 16th-18th. The summit will feature 75 companies and over 300 investors, connecting smallcap and microcap firms with qualified investors.
ENDRA is known for its innovative Thermo-Acoustic Enhanced UltraSound (TAEUS) technology, which aims to revolutionize ultrasound by enabling visualization of tissue composition and function. This technology will initially focus on assessing fat in the liver for early detection of Non-Alcoholic Fatty Liver Disease (NAFLD-NASH).
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announces its participation in two significant virtual medical conferences: The Liver Meeting Digital Experience (TLMdX) from Nov. 13-16, 2020, and the Radiological Society of North America (RSNA) annual meeting from Nov. 29-Dec. 5. This exhibition aims to boost the commercialization of its Thermo Acoustic Enhanced UltraSound (TAEUS®) System, which provides a non-invasive method for assessing liver fat. The company has also submitted a 510(k) application to the FDA for TAEUS® clearance, with CE Mark approval already in place.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) will release its third quarter financial results on November 16, 2020, after U.S. market close. A conference call will follow at 4:30 p.m. ET to discuss results and company updates. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at revolutionizing tissue visualization at a fraction of the cost of traditional imaging methods. TAEUS focuses on assessing liver conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and aims to expand into other clinical applications.
ENDRA Life Sciences Inc. (NASDAQ:NDRA) has been granted European Patent EP 3 294 142 B1, expanding its TAEUS technology applications beyond Non-Alcoholic Fatty Liver Disease (NAFLD). This patent increases ENDRA's total to 75 worldwide, enhancing its commercial prospects with innovative imaging techniques. CEO Francois Michelon noted the importance of this patent as the company ramps up sales efforts in Europe, where they established their first clinical evaluation reference site. The patent potentially opens up a market exceeding $21 billion in liver disease diagnostics.